Endovascular balloon angioplasty for infrainguinal arterial occlusive disease: Efficacy analysis
- PMID: 33768975
- PMCID: PMC7970085
- DOI: 10.5606/tgkdc.dergisi.2021.18573
Endovascular balloon angioplasty for infrainguinal arterial occlusive disease: Efficacy analysis
Abstract
Background: We present early and mid-term clinical outcomes of endovascular revascularization for femoropopliteal involvement of peripheral arterial disease.
Methods: A total of 128 patients (113 males, 15 females; mean age: 63.4±9.9 years; range, 32 to 87 years) who underwent percutaneous transluminal angioplasty for femoropopliteal lesions between August 2016 and April 2018 were analyzed retrospectively. Treatment with Luminor® paclitaxel-coated drug-eluting balloon catheter or bailout therapy with iVolution® self-expanding nitinol stent were performed. Overall patency rates and freedom from reintervention rates were analyzed using the Kaplan-Meier analysis. The primary patency and freedom from reintervention to target lesion rates at 12 and 24 months were evaluated.
Results: Technical success was achieved in 133 (93%) of the interventions with a median follow-up of 11 (range, 1 to 35) months. At 12 and 24 months, the mean overall patency rates were 85.6±3.7% and 66.8±6.7%, respectively and the mean freedom from reintervention to target lesion rates were 91.6±2.9% and 78.1±6.3%, respectively. The primary patency and freedom from reintervention to target lesion rates were significantly higher in the bailout stenting group than the drug-eluting balloon group at 12 months (97.3±2.7% vs. 94.8±6.1%, respectively, p=0.025 and 97.1±2.9% vs. 84.2±5.5%, respectively, p=0.005) and at 24 months (76.9±7.9% vs. 55.8±13.4%, respectively, p=0.025 and 85.2±7.0% vs. 70.2±13.6%, respectively, p=0.005).
Conclusion: Endovascular procedures including drug-eluting balloon and bailout stenting seem to be effective alternative treatment modalities for treatment of infrainguinal peripheral arterial disease and can be also used in patients with long lesions and/or total occlusion of femoropopliteal arteries.
Keywords: Bail-out therapy; drug-eluting balloon; endovascular procedure; percutaneous transluminal angioplasty; peripheral arterial disease.
Copyright © 2021, Turkish Society of Cardiovascular Surgery.
Conflict of interest statement
Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Figures
Similar articles
-
Perioperative intravenous Iloprost therapy in addition to percutaneous transluminal angioplasty improves patency for peripheral arterial occlusive disease.Perfusion. 2024 Oct;39(7):1363-1370. doi: 10.1177/02676591231193265. Epub 2023 Aug 2. Perfusion. 2024. PMID: 37531578
-
Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease.J Am Coll Cardiol. 2019 Feb 19;73(6):667-679. doi: 10.1016/j.jacc.2018.11.039. J Am Coll Cardiol. 2019. PMID: 30765033 Clinical Trial.
-
Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multicenter, randomized trial.Circulation. 2013 Jun 25;127(25):2535-41. doi: 10.1161/CIRCULATIONAHA.113.001849. Epub 2013 May 21. Circulation. 2013. PMID: 23694965 Clinical Trial.
-
Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.J Vasc Surg. 2019 Sep;70(3):981-995.e10. doi: 10.1016/j.jvs.2019.01.080. Epub 2019 May 21. J Vasc Surg. 2019. PMID: 31126769
-
Endovascular Intervention for the Treatment of Trans-Atlantic Inter-Society Consensus (TASC) D Femoropopliteal Lesions: A Systematic Review and Meta-Analysis.Cardiovasc Revasc Med. 2021 Jan;22:52-65. doi: 10.1016/j.carrev.2020.06.014. Epub 2020 Jun 12. Cardiovasc Revasc Med. 2021. PMID: 32563709
References
-
- 2014 "IN. PACT Admiral" Drug-Coated Balloon From Medtronic Outperforms Standard Angioplasty In Landmark Study. Medtronic. News and Information. Available at: http:// newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irolnewsArticle& ID=1916027.
-
- Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G, VIVA Physicians Inc Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007;69:910–919. - PubMed
-
- Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–1365. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous